Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

By M. Pfreundschuh, J. Schubert, M. Ziepert, R. Schmits, M. Mohren, E. Lengfelder, M. Reiser, C. Nickenig, M. Clemens, N. Peter and 16 more. The Lancet Oncology, 2008

1,090 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/fb45652f16c0b7a7fe2758efdffad25d20a053e3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Nicolas Stransky
2. Eric S. Lander

Citations in the corpus

• Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012, background): “MYC gene rearrangement is associated with a high risk of CNS relapse [43].”
• Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing (2012, methodology): “Barcoded exon capture libraries were then pooled into batches and sequenced on Illumina HiSeq instruments (76-bp paired-end reads) (2, 3).”